FDA Warns of Decreased Survival in Some Patients Treated with Keytruda, Tecentriq Monotherapy
May 22nd 2018Officials with the FDA alerted health care professionals about reduced efficacy for some patients taking pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for metastatic urothelial cancer in ongoing clinical trials.
Read More